Patents by Inventor Shana Frederickson
Shana Frederickson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9409964Abstract: Antibodies or fragments thereof having CDR regions replaced or fused with biologically active peptides are described. Flanking sequences may optionally be attached at one or both the carboxy-terminal and amino-terminal ends of the peptide in covalent association with adjacent framework regions. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.Type: GrantFiled: April 29, 2014Date of Patent: August 9, 2016Assignee: Alexion Pharmaceuticals, Inc.Inventors: Katherine S. Bowdish, Shana Frederickson, Mark Renshaw
-
Publication number: 20150004700Abstract: Antibodies or fragments thereof having CDR regions replaced or fused with biologically active peptides are described. Flanking sequences may optionally be attached at one or both the carboxy-terminal and amino-terminal ends of the peptide in covalent association with adjacent framework regions. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.Type: ApplicationFiled: April 29, 2014Publication date: January 1, 2015Applicant: ALEXION PHARMACEUTICALS, INC.Inventors: Katherine S. BOWDISH, Shana FREDERICKSON, Mark RENSHAW
-
Patent number: 8771932Abstract: Antibodies or fragments thereof having CDR regions replaced or fused with biologically active peptides are described. Flanking sequences may optionally be attached at one or both the carboxy-terminal and amino-terminal ends of the peptide in covalent association with adjacent framework regions. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.Type: GrantFiled: January 26, 2009Date of Patent: July 8, 2014Assignee: Alexion Pharmaceuticals, Inc.Inventors: Katherine S. Bowdish, Mark Renshaw, Shana Frederickson
-
Patent number: 8674082Abstract: Antibodies or fragments thereof having at least two CDR regions replaced or fused with biologically active peptides are described. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.Type: GrantFiled: July 1, 2008Date of Patent: March 18, 2014Assignee: Alexion Pharmaceuticals Inc.Inventors: Katherine S. Bowdish, Shana Frederickson, Mark Renshaw
-
Publication number: 20100041012Abstract: Antibodies or fragments thereof having CDR regions replaced or fused with biologically active peptides are described. Flanking sequences may optionally be attached at one or both the carboxy-terminal and amino-terminal ends of the peptide in covalent association with adjacent framework regions. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.Type: ApplicationFiled: January 26, 2009Publication date: February 18, 2010Applicant: Alexion Pharmaceuticals, Inc.Inventors: Katherine S. Bowdish, Shana Frederickson, Mark Renshaw
-
Publication number: 20090130716Abstract: Antibodies or fragments thereof having at least two CDR regions replaced or fused with biologically active peptides are described. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.Type: ApplicationFiled: July 1, 2008Publication date: May 21, 2009Applicant: Alexion Pharmaceuticals, Inc.Inventors: Katherine S. Bowdish, Shana Frederickson, Mark Renshaw
-
Patent number: 7482435Abstract: Antibodies or fragments thereof having CDR regions replaced or fused with biologically active peptides are described. Flanking sequences may optionally be attached at one or both the carboxy-terminal and amino-terminal ends of the peptide in covalent association with adjacent framework regions. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.Type: GrantFiled: December 5, 2001Date of Patent: January 27, 2009Assignee: Alexion Pharmaceuticals, Inc.Inventors: Katherine S. Bowdish, Shana Frederickson, Mark Renshaw
-
Publication number: 20090011471Abstract: Nucleic acid sequences encoding at least a portion of a polypeptide are directly incorporated into a plasmid by DNA polymerization or reverse transcription of a nucleic acid template. In particularly preferred embodiments, nucleic acid sequences encoding at least a portion of an antibody are directly incorporated into a plasmid by reverse transcription of messenger RNA (mRNA).Type: ApplicationFiled: June 12, 2007Publication date: January 8, 2009Inventors: Katherine S. Bowdish, Shana Frederickson, Ying-Chi Lin, Mark Renshaw, Martha Wild, John McWhirter
-
Patent number: 7414111Abstract: Methods of amplifying nucleic acid have now been discovered which include the steps of: a) annealing a primer to a template nucleic acid sequence, the primer having a first portion which anneals to the template and a second portion of predetermined sequence; b) synthesizing a polynucleotide that anneals to and is complementary to the portion of the template between the location at which the first portion of the primer anneals to the template and the end of the template, the polynucleotide having a first end and a second end, wherein the first end incorporates the primer; c) separating the polynucleotide synthesized in step (b) from the template; d) annealing a nested oligonucleotide to the second end of the polynucleotide synthesized in step (b), the nested oligonucleotide having a first portion that anneals to the second end of the polynucleotide and a second portion having the same predetermined sequence as the second portion of the primer; e) extending the polynucleotide synthesized in step (b) to provideType: GrantFiled: December 15, 2003Date of Patent: August 19, 2008Assignee: Alexion Pharmaceuticals, Inc.Inventors: Toshiaki Maruyama, Katherine S. Bowdish, Shana Frederickson, Mark Renshaw
-
Patent number: 7396917Abstract: Antibodies or fragments thereof having at least two CDR regions replaced or fused with biologically active peptides are described. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.Type: GrantFiled: December 2, 2002Date of Patent: July 8, 2008Assignee: Alexion Pharmaceuticals, Inc.Inventors: Katherine S. Bowdish, Shana Frederickson, Mark Renshaw
-
Patent number: 7306906Abstract: Methods of amplifying nucleic acid have now been discovered which include the steps of: a) annealing a primer to a template nucleic acid sequence, the primer having a first portion which anneals to the template and a second portion of predetermined sequence; b) synthesizing a polynucleotide that anneals to and is complementary to the portion of the template between the location at which the first portion of the primer anneals to the template and the end of the template, the polynucleotide having a first end and a second end, wherein the first end incorporates the primer; c) separating the polynucleotide synthesized in step (b) from the template; d) annealing a nested oligonucleotide to the second end of the polynucleotide synthesized in step (b), the nested oligonucleotide having a first portion that anneals to the second end of the polynucleotide and a second portion having the same predetermined sequence as the second portion of the primer; e) extending the polynucleotide synthesized in step (b) to provideType: GrantFiled: September 19, 2002Date of Patent: December 11, 2007Assignee: Alexion Pharmaceuticals, Inc.Inventors: Toshiaki Maruyama, Shana Frederickson, Katherine S. Bowdish, Mark Renshaw, Ying-Chi Lin
-
Publication number: 20070009957Abstract: Expression vectors used for expression of mouse Fab libraries and expression of individual clones have portions of mouse constant regions replaced with human constant regions while maintaining desired cloning sites.Type: ApplicationFiled: March 4, 2004Publication date: January 11, 2007Applicant: Alexion Pharmaceuticals, Inc.Inventors: Katherine Bowdish, Shana Frederickson, Toshiaki Maruyama
-
Publication number: 20060024666Abstract: Humanized anti-VEEV antibodies can be used to prevent and/or neutralize viral infection.Type: ApplicationFiled: May 13, 2003Publication date: February 2, 2006Inventors: Shana Frederickson, Chris Hinkel
-
Patent number: 6919189Abstract: Templates that are engineered to contain a predetermined sequence and a hairpin structure are provided by a nested oligonucleotide extension reaction. The engineered template allows Single Primer Amplification (SPA) to amplify a target sequence within the engineered template. In particularly useful embodiments, the target sequences from the engineered templates are cloned into expression vehicles to provide a library of polypeptides or proteins, such as, for example, an antibody library.Type: GrantFiled: December 10, 2001Date of Patent: July 19, 2005Assignee: Alexion Pharmaceuticals, Inc.Inventors: Katherine S. Bowdish, Shana Frederickson, John McWhirter, Maruyama Toshiaki
-
Publication number: 20050079489Abstract: Templates that are engineered to contain a predetermined sequence and a hairpin structure are provided by a nested oligonucleotide extension reaction. The engineered template allows Single Primer Amplification (SPA) to amplify a target sequence within the engineered template. In particularly useful embodiments, the target sequences from the engineered templates are cloned into expression vehicles to provide a library of polypeptides or proteins, such as, for example, an antibody library.Type: ApplicationFiled: December 10, 2001Publication date: April 14, 2005Inventors: Katherine Bowdish, Shana Frederickson, John McWhirter, Maruyama Toshiaki
-
Publication number: 20040258699Abstract: Human neutralizing antibodies (full-length or functional fragments) are useful as anti-toxins or anti-infectives with respect to infective agents such as, for example, anthrax, botulinum, smallpox, Venezuelan equine encephalomyelitis virus (VEEV), West Nile virus (WNV) and the like.Type: ApplicationFiled: June 2, 2003Publication date: December 23, 2004Inventors: Katherine S. Bowdish, Shana Frederickson, Martha A. Wild, Toshiaki Maruyama, Mary Jean Nolan
-
Publication number: 20040253242Abstract: Antibodies or fragments thereof having CDR regions replaced or fused with biologically active peptides are described. Flanking sequences may optionally be attached at one or both the carboxy-terminal and amino-terminal ends of the peptide in covalent association with adjacent framework regions. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.Type: ApplicationFiled: December 15, 2003Publication date: December 16, 2004Inventors: Katherine S. Bowdish, Shana Frederickson, Mark Renshaw, Cecelia Orencia
-
Publication number: 20040197911Abstract: A phage genome is engineered to include a novel restriction site at one of two different positions. In a first embodiment, a restriction site is inserted into the phage genome between the end of gene IV and the MOS hairpin which serves as a phage packaging signal for newly synthesized single strands of phage DNA. In a second embodiment, a restriction site is inserted into the phage genome after the MOS hairpin and prior to the minus strand origin. Once the phage genome is modified to contain the new restriction site, the vector can be engineered to be a “88” vector by inserting at the new restriction site a nucleotide sequence encoding at least a functional domain of pVIII and at least a first cloning site for receiving a gene encoding a polypeptide to be displayed and, optionally a second cloning site for receiving a second gene encoding a polypeptide capable of dimerizing with the polypeptide to be displayed.Type: ApplicationFiled: April 26, 2002Publication date: October 7, 2004Inventors: Katherine S. Bowdish, Shana Frederickson, Martha Wild
-
Patent number: RE41365Abstract: Templates that are engineered to contain a predetermined sequence and a hairpin structure are provided by a nested oligonucleotide extension reaction. The engineered template allows Single Primer Amplification (SPA) to amplify a target sequence within the engineered template. In particularly useful embodiments, the target sequences from the engineered templates are cloned into expression vehicles to provide a library of polypeptides or proteins, such as, for example, an antibody library.Type: GrantFiled: February 18, 2009Date of Patent: June 1, 2010Assignee: Alexion Pharmaceuticals, Inc.Inventors: Katherine S. Bowdish, Shana Frederickson, John McWhirter, Toshiaki Maruyama, Ying-Chi Lin
-
Patent number: RE42130Abstract: Phagemid vectors containing a sequence of features between a Col E1 origin and an f1 origin are useful for display of polypeptides or proteins, including antibody libraries.Type: GrantFiled: November 26, 2007Date of Patent: February 8, 2011Assignee: Alexion Pharmaceuticals, Inc.Inventors: Katherine S. Bowdish, Shana Frederickson, Martha Wild